API Product   :    Eribulin Mesylate*
CEP   :    -
WCC   :    -
Therapeutic Use    :    Anticancer
Originator   :    Eisai
CAS No.    :    253128-41-5
Trade Name.   :    Halaven
Molecular Weight   :    729.90 g/mol
Molecular Formula   :    C40H59NO11
Eribulin mesylate is approved to treat: Breast cancer that has metastasized (spread to other parts of the body). It is used in patients who have already been treated with an anthracycline and a taxane.
Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma.